Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

NGNE

Neurogene (NGNE)

Neurogene Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NGNE
DateTimeSourceHeadlineSymbolCompany
11/18/20244:25PMBusiness WireNeurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
11/18/20245:45AMBusiness WireNeurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
11/11/20243:01PMBusiness WireNeurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
11/04/20246:30AMBusiness WireNeurogene Announces Oversubscribed $200 Million Private PlacementNASDAQ:NGNENeurogene Inc
10/21/20246:30AMBusiness WireNeurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
08/09/20246:30AMBusiness WireNeurogene Reports Second Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
08/07/20246:30AMBusiness WireNeurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
07/02/20246:30AMBusiness WireNeurogene to Participate in BMO Genetic Medicines SummitNASDAQ:NGNENeurogene Inc
07/01/20246:30AMBusiness WireNeurogene Announces Addition to Russell 3000® IndexNASDAQ:NGNENeurogene Inc
06/18/20248:26AMBusiness WireNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
06/05/20246:30AMBusiness WireNeurogene to Participate in Upcoming ConferencesNASDAQ:NGNENeurogene Inc
06/03/20246:30AMBusiness WireNeurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot ProgramNASDAQ:NGNENeurogene Inc
05/10/20246:30AMBusiness WireNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
05/07/20245:19AMBusiness WireNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingNASDAQ:NGNENeurogene Inc
04/22/20243:36PMBusiness WireNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingNASDAQ:NGNENeurogene Inc
03/18/20243:14PMBusiness WireNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
03/04/20246:30AMBusiness WireNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialNASDAQ:NGNENeurogene Inc
02/29/20246:30AMBusiness WireNeurogene to Participate in Upcoming Investor ConferencesNASDAQ:NGNENeurogene Inc
01/16/20246:00AMBusiness WireNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNASDAQ:NGNENeurogene Inc
01/05/20246:00AMBusiness WireNeurogene Announces Business Update and 2024 OutlookNASDAQ:NGNENeurogene Inc
 Showing the most relevant articles for your search:NASDAQ:NGNE